Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.67 |
| ▸ | CTSB | P07858 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709751 | 0.95 | CTSL (0.61) | CTSLCTSBCTSSCAPN1 | |
| SCHEMBL23824444 | 0.88 | CTSL (0.73) | CTSLCTSBCTSSCAPN1CTSK | |
| SCHEMBL23824529 | 0.88 | CTSL (0.73) | CTSLCTSBCTSSCAPN1CTSK | |
| SCHEMBL24710073 | 0.86 | CTSL (0.65) | CTSLCTSBCTSSCAPN1CTSK | |
| SCHEMBL24709756 | 0.85 | CTSL (0.64) | CTSLCTSBCTSSCAPN1CTSK | |
| SCHEMBL24582575 | 0.84 | CTSL (0.67) | CTSLCTSBCTSSCAPN1CTSK | |
| SCHEMBL29609480 | 0.84 | CTSL (0.68) | CTSLCTSBCTSS | |
| SCHEMBL24582719 | 0.82 | CTSL (0.55) | CTSLCTSBCTSS | |
| SCHEMBL24709884 | 0.81 | CTSL (0.59) | CTSLCTSBCTSSCAPN1CTSK | |
| SCHEMBL34468083 | 0.80 | CTSL (0.64) | CTSLCTSBCTSSCAPN1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834408-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220396550-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834408-B2 | Compounds for the treatment of SARS | ACE2, SARS1, ACE | CTSL 70/4885CTSB 33/4885CTSS 39/4885 |
| US-20220396550-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, SARS1, ACE | CTSL 70/4885CTSB 33/4885CTSS 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.